The global lixisenatide market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in June 2021, Novo Nordisk received US Food and Drug Administration (FDA) approval of Wegovy (semaglutide) injection for chronic weight management in adults with obesity with one weight-related condition such as high blood pressure, type-2 diabetes, or cholesterol. Furthermore, in June 2019, Novo Nordisk has received US Food and Drug Administration Approval of expanded use of Victoza injection to lower the blood sugar along with diet and exercise in children and adolescents aged 10-17 years with type-2 diabetes. The Victoza also plays a major role in reducing the risk of cardiovascular events such as heart attacks, stroke, or deaths in adults with type-2 diabetes mellitus with known heart disease. Thus, such approvals from the US FDA are anticipated to drive the growth of the global lixisenatide market during the forecast period.
Browse the full report
description of “Global Lixisenatide Market Size, Share
& Trends Report by Type (Tablets and Liquid Injection) and by Application
(Hospitals, Clinic, Medical Center and Other) Forecast (2022-2028)“at https://www.omrglobal.com/industry-reports/lixisenatide-market
The rise in the prevalence of obesity due to urbanization is one of the major factors driving the global lixisenatide market. According to the data published by World Health Organization (WHO) in 2021, 55% of the world population lives in urban areas, and is expected to rise to 68% by 2050. Approximately 40% of urban dwellers have no access to sanitization services and adequate drinking water further leading to an increase in the burden of non communicable diseases such as asthma, diabetes associated with obesity. Moreover, physical inactivity in the cities lacking transit and walking infrastructure are anticipated to increase the prevalence of obesity among the population, further driving the growth of the global lixisenatide market during the forecast period.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Zealand Pharma, Sanofi Aventis U.S Llc, Elli Lily & Co, GlaxoSmithKline Plc. more among others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Lixisenatide Market Report Segment
By Type
By Application
Global Lixisenatide Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World